

SITUATION REPORT

Nigeria Centre For Disease Control and Prevention (NCDC)

NCDC.GOV.NG

PLOT 800 EBITU UKIWE STREET, JABI ABUJA, NIGERIA TOLL FREE CALL: 6232 E:info@ncdc.gov.ng

@NCDCgov 🚮 🎔 🗿


TITLE:	UPDATE ON MPOX (MPX) IN NIGERIA
SERIAL NUMBER:	8
EPI-WEEK:	29-32
DATE:	August 11, 2024

Key Indicators

Reporting Year	Reporting week	Confirmed(Suspected) cases	Death (Confirmed cases)	Case Fatality Rate %(CFR)	States Affected (Confirmed cases)	LGAs Affected (Confirmed cases)
2024 Current	Week 29-32	2(51)	0	0.0	2	2
2024 Cumulative	Week 1-32	39(786)	0	0.0	19	30
2023 Cumulative	Week 1- 52	98(1182)	2	2.0	25 +FCT	65

Highlights

- **51** new suspected cases were reported in Epi week 29-32, 2024, compared with 102 cases reported in the previous four weeks (Epi week 25-28) from eighteen (18) States across 26 LGAs.
- Two (2) confirmed cases were reported in week 29-32 compared with seven (7) confirmed cases reported in week 25-28, 2024.



States	Confirmed Case in Epi weeks 28-32
Ebonyi	1
Enugu	1
Total	2

Suspected cases recorded in Week 29-32

- Nineteen (19) States + FCT have recorded at least one confirmed Mpox case across thirty (30) Local Government Areas in 2024
- Since September 2017, 4603 suspected cases have been reported from 36 states and FCT, with 1125 confirmed cases (24.4%) from 35 States and FCT. Males (~70%) are predominantly affected. Seventeen (17) deaths have been recorded since 2017.
- The National Mpox multi-sectoral & multi-partner Technical Working Group (TWG) continues to





















Epidemic curve of reported mpox cases since January 2024 till date.



Age and sex distribution of Nigeria confirmed mpox cases from January 2024 till date























Map of Nigeria showing States with suspected and confirmed Mpox Cases from January 2024 till date.



Mpox Epi Week Summary, from Week 1 -32, 2024
























Nigeria confirmed Mpox cases by the year of incidence- September 2017 to 11th August 2024

Summary statistics for annual Nigeria Mpox cases by reporting year, September 2017 – 11th August 2024

Reporting year	Suspected cases	Confirmed cases	Deaths (Confirmed cases)	Case Fatality Rate % (CFR)	States Affected (Confirmed cases)	LGAs Affected (Confirmed cases)
2024	786	39	0	0.0	19 + FCT	30
2023	1182	98	2	2.0	25 +FCT	65
2022	2123	762	7	0.9	34 + FCT	238
2021	98	34	0	0.0	8 + FCT	25
2020	35	8	0	0.0	5	7
2019	65	47	1	2.1	11	26
2018	116	49	1	2.0	13	25
2017	198	88	6	6.8	14 + FCT	33

Age distribution of cumulative number of confirmed Mpox cases September 2017 – 11th August 2024

Age Group	2017	2018	2019	2020	2021	2022	2023	2024	Total
0-10 Years	7	5	1	0	1	125	21	14	174
11-20 Years	12	4	1	0	4	123	8	6	158
21-30 Years	34	13	13	4	10	187	24	6	291
31- 40 Years	26	17	22	4	13	205	21	8	316
41-50 Years	9	10	9	0	5	89	17	5	144
> 50 Years	0	0	1	0	1	33	7	0	42
Total	88	49	47	8	34	762	98	39	1125



















Nigeria confirmed Mpox cases by State, September 2017 – 11th August 2024

S/N	State	2017	2018	2019	2020	2021	2022	2023	2024	Total
1	Lagos	4	1	15	4	6	188	27	1	246
2	Rivers	25	14	7	1	5	37	4	2	95
3	Bayelsa	19	11	7	0	6	45	2	5	95
4	Abia	1	2	0	0	0	58	6	1	68
5	Delta	3	6	10	1	9	31	3	2	65
6	Imo	5	2	1	0	0	45	5	1	59
7	Ogun	0	0	0	0	1	40	17	0	58
8	Ondo	0	0	0	0	0	40	2	0	42
9	Edo	4	1	1	0	4	27	4	0	41
10	FCT	5	0	0	0	1	25	4	2	37
11	Anambra	0	1	1	0	0	25	0	2	29
12	Cross River	9	3	1	0	1	12	1	4	31
13	Kwara	0	0	0	0	0	21	0	0	21
14	Plateau	0	2	0	1	0	16	0	2	21
15	Akwa Ibom	6	0	1	0	0	12	4	3	26
16	Nasarawa	1	1	0	0	0	17	1	1	21
17	Adamawa	0	0	0	0	0	16	0	0	16
18	Oyo	1	3	2	0	0	10	1	1	18
19	Kaduna	0	0	0	0	0	15	2	1	18
20	Ebonyi	0	0	0	1	0	12	1	1	15
21	Benue	2	0	0	0	0	10	0	3	15
22	Borno	0	0	0	0	0	11	2	0	13
23	Enugu	1	2	1	0	0	4	4	4	16
24	Katsina	0	0	0	0	0	8	1	0	9
25	Taraba	0	0	0	0	0	7	0	0	7
26	Kano	0	0	0	0	0	7	0	0	7
27	Gombe	0	0	0	0	0	6	0	0	6
28	Kogi	0	0	0	0	0	5	2	0	7
29	Osun	0	0	0	0	0	5	1	1	7
30 31	Ekiti Niger	0	0	0	0	0	1	1	0	3
32	Kebbi	0	0	0	0	0	2	1	1	4
33	Bauchi	0	0	0	0	0	1	0	0	1
34	Zamfara	0	0	0	0	0	1	0	1	2
35	Yobe	0	0	0	0	0	1	0	0	1
36	Jigawa	0	0	0	0	0	0	1	0	1
	Grand	88	49	47	8	34	762	98	39	1125
	Total									

Notes on this report.

Data Source

Information for this disease was case-based data retrieved from the National Mpox Emergency Operations Centre.



















Case definitions

Suspected case

An acute illness with fever >38.3°C, intense headache, lymphadenopathy, back pain, myalgia, and intense asthenia followed one to three days later by a progressively developing rash often beginning on the face (most dense) and then spreading elsewhere on the body, including soles of feet and palms of the hand.

Probable case

A case that meets the clinical case definition, not laboratory-confirmed but has an epidemiological link to a confirmed case.

Confirmed case.

A clinically compatible case that is laboratory-confirmed

Contact

Any person who has been in direct or indirect contact with a confirmed case since the onset of symptoms, i.e., • contact with skin lesions, oral secretions, urine, feces, vomitus, blood, sexual contact, sharing a common space (anyone who has been in proximity with or without physical contact with a confirmed case)

Calculations

Case Fatality Rate (CFR) for this disease is reported for confirmed cases only. •

Mpox Prevention Measures

To prevent the spread of mpox:

- Avoid close contact with individuals showing symptoms, particularly those with rashes or skin lesions.
- Practice good hand hygiene by regularly washing hands with soap and water or using an alcohol-based hand sanitizer.
- Wear protective gear (gloves, masks) when caring for someone with suspected or confirmed mpox.
- Avoid contact with animals that may harbor the virus, such as rodents and primates, especially in areas where mpox is known to occur.
- Ensure meat is thoroughly cooked before consumption.

Actions for Healthcare Providers

- Be vigilant for patients presenting with fever, rash, and other mpox symptoms, especially if they have a history of travel to affected areas or contact with suspected cases.
- Promptly isolate suspected cases to prevent transmission within healthcare settings.
- Notify the relevant public health authorities immediately upon identifying a suspected case.
- Educate patients on the importance of reporting symptoms early and adhering to isolation guidelines if diagnosed with mpox.

Contact

NCDC Toll-free Number: 6232 | SMS: 08099555577 | WhatsApp: 07087110839

www.ncdc.gov.ng X: @NCDCgov Facebook: NCDCgov



















